Search Results - "Ettl, J"

Impact of palbociclib plus letrozole on patient-reported health-related quality of life: results from the PALOMA-2 trial by Rugo, H.S., Diéras, V., Gelmon, K.A., Finn, R.S., Slamon, D.J., Martin, M., Neven, P., Shparyk, Y., Mori, A., Lu, D.R., Bhattacharyya, H., Bartlett, C.H.u.a.n.g., Iyer, S., Johnston, S., Ettl, J., Harbeck, N.

“…Patient-reported outcomes are integral in benefit–risk assessments of new treatment regimens. The PALOMA-2 study provides the largest body of evidence for…”
Get full text

Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up by Rugo, H. S., Finn, R. S., Diéras, V., Ettl, J., Lipatov, O., Joy, A. A., Harbeck, N., Castrellon, A., Iyer, S., Lu, D. R., Mori, A., Gauthier, E. R., Bartlett, C. Huang, Gelmon, K. A., Slamon, D. J.

“…Purpose In the initial PALOMA-2 (NCT01740427) analysis with median follow-up of 23 months, palbociclib plus letrozole significantly prolonged progression-free…”
Get full text

Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial by Litton, J.K., Hurvitz, S.A., Mina, L.A., Rugo, H.S., Lee, K.-H., Gonçalves, A., Diab, S., Woodward, N., Goodwin, A., Yerushalmi, R., Roché, H., Im, Y.-H., Eiermann, W., Quek, R.G.W., Usari, T., Lanzalone, S., Czibere, A., Blum, J.L., Martin, M., Ettl, J.

“…In EMBRACA, talazoparib prolonged progression-free survival versus chemotherapy (hazard ratio [HR] 0.542 [95% confidence interval (CI) 0.413-0.711]; P <…”
Get full text

Quality of life with talazoparib versus physician’s choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation: patient-reported outcomes from the EMBRACA phase III trial by Ettl, J., Quek, R.G.W., Lee, K.-H., Rugo, H.S., Hurvitz, S., Gonçalves, A., Fehrenbacher, L., Yerushalmi, R., Mina, L.A., Martin, M., Roché, H., Im, Y.-H., Markova, D., Bhattacharyya, H., Hannah, A.L., Eiermann, W., Blum, J.L., Litton, J.K.

“…In the EMBRACA phase III trial, talazoparib (1mg daily, orally) demonstrated a statistically significant improvement in PFS versus physician’s choice of…”
Get full text

Biological nitrogen fixation and biomass accumulation within poplar clones as a result of inoculations with diazotrophic endophyte consortia by Knoth, Jenny L., Kim, Soo‐Hyung, Ettl, Gregory J., Doty, Sharon L.

“…Sustainable production of biomass for bioenergy relies on low-input crop production. Inoculation of bioenergy crops with plant growth-promoting endophytes has…”
Get full text

Clinical considerations of the role of palbociclib in the management of advanced breast cancer patients with and without visceral metastases by Turner, N.C., Finn, R.S., Martin, M., Im, S.-A., DeMichele, A., Ettl, J., Diéras, V., Moulder, S., Lipatov, O., Colleoni, M., Cristofanilli, M., Lu, D.R., Mori, A., Giorgetti, C., Iyer, S., Bartlett, C. Huang, Gelmon, K.A.

“…This report assesses the efficacy and safety of palbociclib plus endocrine therapy (ET) in women with hormone receptor-positive, human epidermal growth factor…”
Get full text

Environmental drivers of forest structure and stem turnover across Venezuelan tropical forests by Vilanova, Emilio, Ramírez-Angulo, Hirma, Torres-Lezama, Armando, Aymard, Gerardo, Gámez, Luis, Durán, Cristabel, Hernández, Lionel, Herrera, Rafael, van der Heijden, Geertje, Phillips, Oliver L, Ettl, Gregory J

“…Using data from 50 long-term permanent plots from across Venezuelan forests in northern South America, we explored large-scale patterns of stem turnover,…”
Get full text

The Effect of Microbial Endophyte Consortia on Pseudotsuga menziesii and Thuja plicata Survival, Growth, and Physiology Across Edaphic Gradients by Aghai, Matthew M, Khan, Zareen, Joseph, Matthew R, Stoda, Aubrey M, Sher, Andrew W, Ettl, Gregory J, Doty, Sharon L

“…Increased frequency of droughts and degraded edaphic conditions decreases the success of many reforestation efforts in the Pacific Northwest. Microbial…”
Get full text

Feasibility of quantitative sensory testing (QST) in clinical routine as a tool to evaluate chemotherapy-induced peripheral neuropathy (CIPN) amongst breast cancer patients treated with taxanes by Ioannou, I., Utpadel-Fischler, D., Tölle, T., Kiechle, M., Ettl, J.

Get full text

Hospitalization and supportive care medication (SCM) utilisation in patients (pts) with advanced breast cancer (ABC) and a germline BRCA1/2 mutation (gBRCAm) in EMBRACA by Ettl, J., Quek, R.G.W., Hurvitz, S.A., Goncalves, A., Tudor, I.C., Rugo, H.S.

Get full text

Impact of objective response (OR) on patient-reported outcomes (PRO) in patients (pts) with advanced breast cancer (ABC) and a germline BRCA1/2 (gBRCA) mutation in the phase III EMBRACA trial by Fasching, P.A., Quek, R.G.W., Bhattacharyya, H., Hurvitz, S.A., Rugo, H.S., Ettl, J.

Get full text

RESCUE: Reaching for evidence-based chemotherapy use in endocrine sensitive breast cancer - A prospective non-interventional study on risk assessment by the endopredict test and long-term patient outcome in early luminal breast cancer by Ettl, J., Blohmer, J.-U., Denkert, C., Beier, L., Klein, E., Neuser, P., Keller, M., Untch, M., Wittenberg, M., Kiechle, M.

Get full text

Quality of life with talazoparib after platinum or multiple cytotoxic non-platinum regimens in patients with advanced breast cancer and germline BRCA1/2 mutations: patient-reported outcomes from the ABRAZO phase 2 trial by Hurvitz, S.A., Quek, R.G.W., Turner, N.C., Telli, M.L., Rugo, H.S., Mailliez, A., Ettl, J., Grischke, E., Mina, L.A., Balmaña, J., Fasching, P.A., Bhattacharyya, H., Hannah, A.L., Robson, M.E., Wardley, A.M.

“…Talazoparib (1 mg/day) exhibited promising efficacy and safety in patients with advanced breast cancer during ABRAZO (NCT02034916); this study evaluated…”
Get full text

Patient-reported outcomes (PRO) in patients (pts) with advanced breast cancer and a germline BRCA1/2 mutation (gBRCAm) receiving talazoparib (TALA) vs physician’s choice chemotherapy treatment (PCT): A focus on the EMBRACA triple negative (TNBC) subpopulation by Rugo, H.S., Quek, R., Ettl, J., Hurvitz, S.A., Bhattacharyya, H., Hannah, A.L., Litton, J.K.

Get full text

EMBRACA: Efficacy and safety in comparing talazoparib (TALA) with physician's choice of therapy (PCT) in patients (pts) with advanced breast cancer (aBC) and a germline BRCA mutation (gBRCAm); BRCA1/BRCA2 subgroup analysis by Gonçalves, A., Eiermann, W., Rugo, H.S., Ettl, J., Hurvitz, S.A., Yerushalmi, R., Martín, M., Al-Adhami, M., Tudor, I.C., Blum, J.L., Hannah, A.L., Litton, J.K.

Get full text

EMBRACA: Comparison of efficacy and safety of talazoparib (TALA) and physician's choice of therapy (PCT) in patients (pts) with advanced breast cancer (aBC), a germline BRCA1/2 mutation (gBRCAm), and prior platinum treatment by Martín, M., Eiermann, W., Rugo, H.S., Ettl, J., Hurvitz, S.A., Gonçalves, A., Yerushalmi, R., Markova, D., Tudor, I.C., Blum, J.L., Hannah, A.L., Litton, J.K.

Get full text

Biomarkers in Patients with Metastatic Breast Cancer and the PRAEGNANT Study Network by Fasching, P A, Brucker, S Y, Fehm, T N, Overkamp, F, Janni, W, Wallwiener, M, Hadji, P, Belleville, E, Häberle, L, Taran, F-A, Lüftner, D, Lux, M P, Ettl, J, Müller, V, Tesch, H, Wallwiener, D, Schneeweiss, A

“…Progress has been made in the treatment of metastatic breast cancer in recent decades, but very few therapies use patient or tumor-specific characteristics to…”
Get full text

Increased Biomass of Nursery-Grown Douglas-Fir Seedlings upon Inoculation with Diazotrophic Endophytic Consortia by Zareen Khan, Shyam L. Kandel, Daniela N. Ramos, Gregory J. Ettl, Soo-Hyung Kim, Sharon L. Doty

“…Douglas-fir (Pseudotsuga menziesii) seedlings are periodically challenged by biotic and abiotic stresses. The ability of endophytes to colonize the interior of…”
Get full text

Genexpressionstests zur Prognose und Prädiktion by Ettl, J.

“…Zusammenfassung Mammakarzinome werden längst nicht mehr ausschließlich anhand der klassischen klinikopathologischen Parameter Tumorgröße, Hormonrezeptorstatus,…”
Get full text

613 Analysis of Immediate Breast Reconstruction with the Use of Titanized Polypropylene Mesh (TiLOOP® Bra) by Klein, E, Kiechle, M, Ettl, J, Paepke, D, Paepke, S

Get full text